The IPAY2026 redacted files are out—and they reveal more than you might expect. From CMS’s structured approach to the dynamic role of commercial net price in negotiations, we have analyzed these insights to prepare pharma manufacturers for what lies ahead. The question remains: Are you ready for IPAY2027?

Valuable guidance for manufacturers, from our top ten learnings drawn from our experience supporting manufacturers during the Medicare Drug Price Negotiation Program